Jalandhar Online

Emerging Therapies such as PTH (1-34) (Entera Bio), TransCon PTH (Ascendis Pharma) Expected to Positively Impact the Hypoparathyroidism Market Scenario in the Upcoming Years

 Breaking News
  • No posts were found

Emerging Therapies such as PTH (1-34) (Entera Bio), TransCon PTH (Ascendis Pharma) Expected to Positively Impact the Hypoparathyroidism Market Scenario in the Upcoming Years

May 18
05:30 2021
Emerging Therapies such as PTH (1-34) (Entera Bio), TransCon PTH (Ascendis Pharma) Expected to Positively Impact the Hypoparathyroidism Market Scenario in the Upcoming Years

Hypoparathyroidism Market
DelveInsight’s report “Hypoparathyroidism – Market Insights, Epidemiology, and Market Forecast-2030” provides an in-depth understanding of Hypoparathyroidism, historical and forecasted epidemiology, as well as Hypoparathyroidism market patterns in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

DelveInsight’s report “Hypoparathyroidism – Market Insights, Epidemiology, and Market Forecast-2030” provides an in-depth understanding of Hypoparathyroidism, historical and forecasted epidemiology, as well as Hypoparathyroidism market patterns in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the Key Highlights from the Hypoparathyroidism Market Report

  • According to the report titled “Epidemiology and Diagnosis of Hypoparathyroidism” (2016), the incidence of Hypoparathyroidism in the United States is reported to be 37 per 100 000 person-years.

  • According to Zanocco et al. (2017), Primary Hyperparathyroidism (PHPT) affects 0.2 percent to 0.5 percent of the population in the United States.

  • Hypoparathyroidism Pipeline therapies include PTH(1-34) (Entera Bio), TransCon PTH (Ascendis Pharma) and others.

  • Major players involved in the Hypoparathyroidism market are Entera Bio, Ascendis Pharma, among others.

  • The rise in Hypoparathyroidism market size is a direct result of the growing incidence of Hypoparathyroidism.

To learn more request sample @ Hypoparathyroidism Market Outlook

The Hypoparathyroidism market report includes emerging clinical trends, new drugs, market share of individual therapies, and current and forecasted Hypoparathyroidism market sizes in the 7MM (the United States, the EU5, Germany, Italy, Spain, and France), as well as Japan.

Hypoparathyroidism: Disease Overview

Hypoparathyroidism is a rare endocrine condition characterised by low calcium and high phosphate levels combined with a low or abnormally normal PTH level. The United States and the European Commission have designated hypoparathyroidism as an orphan condition.

Hypoparathyroidism causes a wide variety of physical, behavioural, cognitive, and emotional effects in those who have it. They also experience debilitating symptoms, which can have a significant effect on quality of life and overall productivity, including the ability to work and perform household tasks.

Hypoparathyroidism Epidemiology Segmentation

  • Hypoparathyroidism Total Prevalent Population

  • Hypoparathyroidism Type-Specific Population

  • Hypoparathyroidism Gender-Specific Population

  • Hypoparathyroidism Diagnosed and Treatable Population

Hypoparathyroidism Treatment landscape

The aim of Hypoparathyroidism treatment is to correct hypocalcemia and hyperphosphatemia, as well as to alleviate symptoms and avoid chronic complications.

Standard treatment includes Calcium supplements and activated Vitamin D, namely Calcitriol or Alfacalcidol. Vitamin D2 (Ergocalciferol) or Vitamin D3 (Cholecalciferol) supplements, Magnesium, and Thiazide diuretics.

Hypoparathyroidism Market

The current clinical environment of Hypoparathyroidism in the United States will be guided by increased knowledge and growth programmes. Hypoparathyroidism is expected to grow in popularity by 2030. The introduction of the most awaited therapies like PTH (1-34) and TransCon PTH, which are seen as a challenge to the existing market, is the primary cause of market growth.

For more information visit @ Hypoparathyroidism Treatment Market 

Hypoparathyroidism Pipeline Therapies and Key Companies

  • PTH (1-34): Entera Bio

  • TransCon PTH: Ascendis Pharma

Table of Contents

1.

Report Introduction

2.

Executive Summary of Hypoparathyroidism

3.

Hypoparathyroidism Market Share at a glance

4.

Hypoparathyroidism: Disease Background and Overview

5.

Hypoparathyroidism Epidemiology and Patient Population

6.

Country Wise: Epidemiology of Hypoparathyroidism

7.

Hypoparathyroidism Current Treatment and Medical Practices

8.

Hypoparathyroidism: Marketed Drugs

9.

Current Unmet Needs of Hypoparathyroidism

10.

Hypoparathyroidism Emerging Therapeutics

11.

Hypoparathyroidism– The US Market Analysis

12.

Region-Wise Market size of Hypoparathyroidism

13.

Hypoparathyroidism: Market Barriers

14.

SWOT Analysis

15.

Hypoparathyroidism Market Access and Reimbursement

16.

Appendix

17.

Report Methodology

18.

DelveInsight Capabilities

19.

Disclaimer

20.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

Hypogonadism Market

Get comprehensive historical and forecast analysis of Hypogonadism Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Endo International Plc., AbbVie Inc., Pfizer Inc., Allergan Plc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Categories